Vishal Mungal, MD
Pulmonary Disease · Annandale, VANPI 1134323884
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,100 of the $44,022 with a category attached, or 88.8%. GSK accounts for 92.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $13,711 and has fallen 94.2% since, to $796 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $174.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$41K
- AstraZeneca$2K
- Amgen$271
- Pulmonx Corporation$203
- Mylan Specialty L.p.$197
- Boehringer Ingelheim$113
- plus $691 from 19 others
What the payments were for
- Speaking & faculty fees$39,10089%
- Travel & lodging$670%
- Food & beverage$4,80811%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 119 | $40,783 |
| AstraZeneca | 68 | $1,763 |
| Amgen | 13 | $271 |
| Pulmonx Corporation | 3 | $203 |
| Mylan Specialty L.p. | 9 | $197 |
| Boehringer Ingelheim | 5 | $113 |
| Electromed, Inc. | 6 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| Sanofi | 2 | $53 |
| Insmed, Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Grifols USA, LLC | 2 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Shire North American Group Inc | 2 | $30 |
| Shionogi Inc | 1 | $25 |
| Verona Pharma, Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$19,828
- FASENRA$378
- ZEPHYR DELIVERY CATHETER$161
- PULMONX CHARTIS TABLET CONSOLE$161
- ZEPHYR ENDOBRONCHIAL VALVE$161
- CHARTIS CATHETER$161
- TEZSPIRE$131
- BREZTRI$131
- FARXIGA$131
How this compares
$44,022 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 204 | $170,592 |
| Breo ElliptaFluticasone/Vilanterol | 85 | $44,717 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $25,198 |
| Spiriva RespimatTiotropium Bromide | 32 | $21,720 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $12,443 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $11,399 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $7,017 |
| Arnuity ElliptaFluticasone Furoate | 24 | $6,478 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,826 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $4,065 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,961 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $2,734 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $2,050 |
| Montelukast Sodium | 20 | $231 |
| Azithromycin | 18 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $40,783 | $234,230330 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,763 | $36,59778 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $113 | $28,73750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Annandale
- Eric LibreAnnandale$302K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.